---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-24-000138"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T05:12:03.472902+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Editas reports positive RUBY trial data: 27/28 SCD patients VOE-free, HbF 48% at month 6

## Summary
- As of Oct 29, 2024, 28 SCD patients treated; 27 VOE-free post-reni-cel; median follow-up 9.5 months.
- Mean total hemoglobin increased from 9.8 g/dL at baseline to 13.8 g/dL at Month 6 (n=18).
- Mean HbF percentage reached 48.1% at Month 6; F-cells >90% from Month 4; MCH-F above anti-sickling threshold.
- All evaluable patients engrafted; median time to neutrophil engraftment 23 days, platelet 25 days.
- Two SAEs possibly related to reni-cel reported; safety consistent with myeloablative conditioning.

## SEC filing metadata
- accession: 0001650664-24-000138
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066424000138/0001650664-24-000138-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066424000138/edit-20241206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-24-000138
- JSON: https://secwatch.observer/filing/0001650664-24-000138.json
- Plain text: https://secwatch.observer/filing/0001650664-24-000138.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.